Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aspreva develops Roche's CellCept for autoimmune disorders

Executive Summary

Specialty pharmaceuticals company Aspreva Pharmaceuticals licensed exclusive worldwide rights (excluding Japan) to develop and sell Roche's CellCept (mycophenolate mofetil) for all autoimmune disease applications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register